This content is machine translated Geriatric Small-Cell Lung Cancer Therapeutic Challenges Small-cell lung cancer remains one of the most aggressive types of cancer, particularly among older adults. New molecular insights and modern therapies offer new possibilities, but require careful consideration of...…
View Post 3 min This content is machine translated Small cell lung carcinoma Durvalumab approved as first immunotherapy for patients with LS-SCLC Durvalumab has been approved as a monotherapy in Switzerland for the treatment of adult patients with unresectable small cell lung cancer (LS-SCLC, limited-stage small cell lung cancer) whose disease has...…
View Post 2 min This content is machine translated SCLC Small cell lung cancer in everyday therapy – an update Small cell lung carcinomas must be treated quickly – they usually grow rapidly and form metastases early on. The diagnosis is therefore often only made at an advanced stage. Lung…
View Post 5 min This content is machine translated News from the lung cancer pipeline First targeted substance in KRAS mutation and bispecific immunotherapy While targeted therapies in non-small cell lung cancer (NSCLC) have been on the rise for years, such an option for KRAS-mutatedtumors has been lacking. The small molecule inhibitor Sotorasib, which…
View Post 5 min This content is machine translated Small cell and non-small cell lung cancer Rapid progress through immunotherapy and immunochemotherapy Immunotherapy is one of the milestones of cancer therapy. However, the selection of particularly suitable patients remains a major challenge for first-line use.
View Post 5 min This content is machine translated European Lung Cancer Conference in Geneva Therapy of small cell lung tumors – focus on neutropenia Update on the use of granulocyte colony stimulating factor (G-CSF) in concurrent chemoradiotherapy. Administration in patients with small cell lung cancer may be safer than previously thought.
